We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · March 16, 2021

Intracranial and Extracranial Efficacy of Lorlatinib in ALK-Positive Previously Treated NSCLC

Annals of Oncology


Additional Info

Annals of Oncology
Intracranial and Extracranial Efficacy of Lorlatinib in Patients With ALK-Positive Non-Small-Cell Lung in Cancer Previously Treated With Second-Generation ALK TKIs
Ann. Oncol 2021 Feb 24;[EPub Ahead of Print], E Felip, AT Shaw, A Bearz, DR Camidge, BJ Solomon, JR Bauman, TM Bauer, S Peters, F Toffalorio, A Abbattista, H Thurm, G Peltz, R Wiltshire, B Besse

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading